Related by context. All words. (Click for frequent words.) 71 cisplatin resistant 70 kidney urologic 69 K ras mutations 69 metastatic colorectal 69 non mutated KRAS 69 Gleevec resistant 68 demonstrated antitumor activity 68 potent inducer 68 epithelial tumors 68 antimitotic 68 castrate resistant 68 mutated K ras 67 Ph + acute lymphoblastic 67 endocrine therapies 67 papillary renal cell carcinoma 67 ovarian pancreatic 67 mTOR inhibitors 67 accumulate preferentially 67 CYT# potent vascular disrupting 67 demethylating agent 67 KRAS mutated 67 lymphoid tumors 67 essential thrombocythemia ET 67 KRAS mutations 67 kinase inhibition 67 T#I [002] 67 BRCA deficient 67 ERBB2 66 pancreatic adenocarcinoma 66 sarcomatoid 66 retinoic acid receptor 66 MCSP respectively 66 #T# L1 66 pancreatic lung 66 haematopoietic 66 androgen independent 66 mda 7 66 lymphoid malignancies 66 humanized monoclonal antibodies 66 Li Fraumeni 66 oral picoplatin 66 proliferative disorders 66 gastrointestinal stromal tumors GISTs 66 chronic myeloid 66 K ras gene 66 BRAF mutant 66 leukemia multiple myeloma 66 refractory Hodgkin 66 fusion enhancers 65 androgen receptor AR 65 cMET 65 HER2 neu 65 Vidaza ® 65 thymidylate synthase TS 65 syngeneic 65 xenograft models 65 refractory colorectal cancer 65 histologies 65 poly ADP ribose polymerase 65 selective kinase inhibitor 65 BRAF V#E 65 antisense inhibitors 65 immune modulating 65 ovarian breast 65 lymphomas leukemias 65 5 fluorouracil leucovorin 65 BRAF V#E mutation 65 targets EpCAM expressing 65 hepatoma 65 Xanafide 65 V#F mutation 65 LRP5 65 EGFR mutation positive 65 metastatic gastric 65 leukemia myeloma 65 tumorigenicity 65 PCA3 gene 65 IGF IR 65 chemoresistant 65 Alfacell proprietary ribonuclease 65 K RAS 65 KRAS oncogene 65 refractory chronic lymphocytic 65 LHRH receptor positive 65 oligodendrogliomas 65 ERK signaling 65 Flt3 64 p# biomarker 64 receptor inhibitor 64 prostate carcinoma 64 castration resistant 64 invasive lobular 64 c MET 64 vinca alkaloid 64 castrate resistant prostate cancer 64 Fc gamma receptor 64 mesenchymal cell 64 FGFR3 64 personalized immunotherapy 64 mutated KRAS 64 pathophysiological effects 64 nonsmall cell lung cancer 64 castration resistant hormone refractory 64 colon carcinoma 64 HuCNS SC ® 64 cytolytic 64 Ribavirin causes 64 mutated p# 64 PIK3CA 64 targeted antifolate 64 HER2 overexpression 64 orthotopic model 64 FLT3 64 TTR amyloidosis 64 targeting CD# 64 relapsed MM 64 AGTR1 64 myelofibrosis polycythemia vera 64 constitutively expressed 64 breast carcinomas 64 neural progenitor 64 Chronic lymphocytic leukemia CLL 64 gemcitabine carboplatin 64 breast pancreatic 64 K ras 64 potently inhibited 64 squamous cell carcinoma SCC 64 Sertoli cell 64 lymphoid organs 64 advanced metastatic renal 64 peritoneal carcinomatosis 64 CD# expressing 64 TRAIL induced apoptosis 64 TNF alpha selectively neutralizing 64 resistant hormone refractory 64 tumors GIST 64 induces apoptosis 64 EGFR HER2 64 chimeric monoclonal antibody 64 neoplastic 64 Granulocyte Colony Stimulating Factor 64 mutant KRAS 64 immuno modulatory 64 lung pancreatic 64 radiosensitivity 64 gastro intestinal inflammation 64 PROSTVAC VF 64 cathepsins 64 multiple myeloma MM 64 taxane therapy 64 novel emulsion formulation 64 neovasculature 64 endometrial ovarian 64 #beta HSD 1 64 Angiotensin converting enzyme 64 therapeutic monoclonal antibody 64 neuroendocrine cancers 64 HGS ETR1 mapatumumab 64 deCODE ProstateCancer TM 64 selectively inhibited 64 T#I mutant 64 CCR9 antagonist 64 undergoing hematopoietic stem 64 effector function 64 5 HT2A serotonin 64 predictive biomarker 63 mTOR mammalian target 63 hypermethylated 63 transgenic rats 63 EGFR mutant 63 dasatinib Sprycel 63 HIV coinfected 63 humoral responses 63 PARP inhibition 63 imatinib Gleevec 63 oncolytic 63 acadesine 63 metastatic pancreatic 63 myeloproliferative 63 idiotype protein 63 antiangiogenic agent 63 STK# [002] 63 candidates Azedra TM 63 recurrent glioblastoma multiforme 63 ovarian carcinoma 63 alkylating agent 63 anti CD3 63 potent suppressor 63 promoter hypermethylation 63 TMEM#B 63 Factor Receptor 63 EGFR receptor 63 Acute myelogenous leukemia 63 mutated KRAS gene 63 lymphoid cells 63 Epigenomics proprietary 63 HGS ETR2 63 Epstein Barr virus EBV 63 hematological diseases 63 RRM1 63 mouse xenograft models 63 pancreatic prostate 63 MAGE A3 ASCI 63 vinca alkaloids 63 interferon lambda 63 Umbilical cord stem cells 63 gefitinib Iressa 63 RNAi therapeutic targeting 63 XL# inhibits 63 Medullary thyroid cancer 63 cutaneous T 63 cervical breast 63 trastuzumab Herceptin R 63 myeloproliferative neoplasms MPNs 63 erlotinib Tarceva ® 63 hepatocellular carcinomas 63 PDGF receptor 63 paclitaxel Taxol 63 metaglidasen 63 chemokine receptors 63 bladder ovarian 63 recurrent metastatic 63 tryptase 63 papillary RCC 63 cyclin dependent kinase inhibitor 63 pancreatic islet cell 63 NS5B polymerase 63 chemo resistant 63 p# alpha [001] 63 antiangiogenic therapy 63 relapsed leukemia 63 HER2 receptor 63 LymphoStat B belimumab 63 antiproliferative effects 63 melanoma ovarian 63 p# deficient 63 isotypes 63 JAK2 kinase 63 metastatic lymph nodes 63 Mesenchymal 63 TTR gene 63 basal cell carcinoma BCC 63 ovarian colon 63 novel VDA molecule 63 GRNOPC1 contains 63 hypereosinophilic syndrome 63 bevacizumab Avastin ® 63 clade B 63 Bayer HealthCare Onyx Pharmaceuticals 63 untreated metastatic melanoma 63 skeletal metastases 63 Aplidin 63 KRAS wild 63 anticancer therapeutics 63 prostate carcinomas 63 soluble tumor necrosis 63 FUSILEV enhances 63 SETDB1 63 immunodeficiency disorders 63 BRCA1 BRCA2 63 colorectal gastric 63 cells hESCs 63 hypercholesterolemia liver 63 chemosensitivity 63 nucleotide analog 63 leukemic stem cells 63 EGFR tyrosine kinase inhibitors 63 DNA methyltransferase inhibitors 63 c MYC 63 FLT3 ITD 63 carcinoma HCC 63 imatinib Gleevec ® 63 viral antigens 62 chemosensitizer 62 multiple sclerosis psoriasis 62 antibody MAb 62 herpes simplex viruses 62 small lymphocytic lymphoma 62 receptor tyrosine kinase inhibitor 62 delay bone metastases 62 experimental autoimmune encephalomyelitis 62 MSH2 62 tyrosine kinase receptor 62 Virulizin ® 62 neoplastic diseases 62 mutant BRAF 62 pleiotropic 62 EGFR activating mutations 62 mucinous 62 EGFR TKIs 62 epigenetic therapies 62 monocytic 62 imatinib resistant 62 CpG island 62 abnormal p# 62 Prognostic factors 62 thalidomide Thalomid 62 Immunotherapeutic 62 CCR5 delta# 62 PTPN# 62 Darinaparsin 62 bone marrow stromal cells 62 commercialize deforolimus 62 MET amplification 62 cyclophilin inhibitors 62 completely resected 62 antibody mediated 62 NKX#.# 62 virotherapy 62 R sorafenib tablets 62 Leukemias 62 humanised monoclonal antibody 62 nonmetastatic 62 indolent follicular non 62 dasatinib Sprycel ® 62 Temodar ® 62 chemoresistance 62 PC# cells 62 missense mutations 62 radiolabeled antibodies 62 survivin expression 62 Chronic lymphocytic leukemia 62 Vidaza R 62 polycythemia vera essential thrombocythemia 62 hormone refractory prostate 62 replicon 62 FOLFIRI alone 62 attach auristatin 62 DU# [002] 62 cells overexpressing 62 myeloablative 62 hepatocellular cancer 62 personalized dendritic 62 inhibits VEGF 62 radiation sensitizer 62 AML acute myeloid 62 Janus kinase 62 HER2 amplified 62 systemic anaplastic large 62 uterine ovarian 62 glial tumors 62 ERK1 2 62 Leydig cell 62 human airway epithelial 62 colorectal carcinoma 62 IAP inhibitor 62 plus dacarbazine 62 orally administered inhibitor 62 type KRAS 62 pT3 62 rhabdoid 62 IMA# 62 Pim kinases 62 microtubule inhibitor 62 hematopoietic progenitors 62 MLH1 62 clonogenic 62 malignant lymphomas 62 histological subtype 62 gastric carcinoma 62 GSTP1 62 metastatic neuroendocrine tumors 62 NPM1 62 gastric adenocarcinoma 62 progressive metastatic prostate 62 MAPK pathway 62 dependent cellular cytotoxicity 62 #T# tumor 62 NS5b 62 gastrointestinal stromal 62 Smac mimetic 62 EGFR TKI 62 leukemia AML 62 Evoltra ® 62 p# biomarkers 62 HLA DR2 62 cyclin E 62 gastric carcinomas 62 diagnostic biomarker 62 T1c 62 adipogenic 62 Gleevec imatinib mesylate 62 Acute myeloid leukemia 62 cell carcinoma RCC 62 Monoclonal antibody 62 MGd 62 ABCB1 62 Dendreon investigational 62 cholangiocarcinoma 62 fibrosarcoma 62 FOLFOX chemotherapy 62 EGFr 62 Interferon beta 62 Shark cartilage 62 alkylating 62 Solazed 62 pain palliation 62 SSc 62 anti PlGF 62 metastatic bladder 62 pancreatic endocrine 62 PITX2 62 lymphoproliferative disorders 62 DNA methylation patterns 62 myeloproliferative diseases 62 androgen receptor antagonist 62 HLA DQ2 62 EGFR mutation status 62 operable breast cancer 62 Canvaxin TM 62 YONDELIS R 62 potently inhibit 62 OvaRex R 62 phenotypic expression 62 paclitaxel Taxol ® 62 Intravenous CP 62 osteogenic 62 depsipeptide 62 Sudhir Agrawal D.Phil 62 alpha folate receptor 62 mouse mammary tumor 62 NKG2D 62 FGFR1 62 Onconase 62 Ceflatonin 62 epithelial tissues 62 topoisomerase II inhibitor 62 NPM1 mutations 62 Thiovir 62 HER2 ErbB2 62 Fibroblast Growth Factor Receptor 62 fibrate drugs 62 Epstein Barr Virus EBV 62 humoral immunity 62 HER2 positive cancers 62 bronchial epithelial cells 62 MCF7 62 CTAP# Capsules 62 Amgen Neulasta R 62 irinotecan doxorubicin oxaliplatin paclitaxel 62 Temsirolimus 62 HER2 expression 62 N. gonorrhoeae 62 splice variants 62 refractory metastatic 62 trastuzumab resistant 62 cytotoxic effects 62 lymphoproliferative disease 62 TLR9 agonist 62 small molecule activators 62 tubulin inhibitor 61 targets Galectin receptors 61 hENT1 61 MVA BN R 61 biologic therapeutics 61 forodesine 61 Platinol ® cisplatin 61 Anthracycline 61 recurrent NSCLC 61 peptide antigens 61 nilotinib Tasigna ® 61 mutational status 61 fluoropyrimidine 61 somatostatin 61 glutamic acid decarboxylase 61 cisplatin carboplatin 61 novel tubulin binding 61 targeted radiotherapeutic 61 histone deacetylase inhibitor 61 potent antiproliferative 61 Fibroblast 61 mCRC patients 61 Epidermal Growth Factor Receptor 61 vinblastine 61 taxane resistant 61 agonistic human 61 leukemias lymphomas 61 Vidaza azacitidine 61 AKT inhibitor 61 neural stem 61 Panzem 61 metastatic renal 61 ActA 61 CD# CD# 61 GRNVAC1 61 Seliciclib 61 apoptotic pathway 61 isoform selective 61 CanAg 61 Diffuse Large B 61 virulence genes 61 M2 subunit 61 chronic lymphocytic 61 tkRNAi 61 ENMD # 61 inflammatory demyelinating 61 adenoviral 61 allogeneic HSCT 61 Sezary syndrome 61 TLR7 agonist 61 alpha1 antitrypsin deficiency 61 clonally 61 TRIOLEX HE# APOPTONE HE# 61 circulating endothelial cells 61 cilengitide 61 GVAX ® 61 transplantation HCT 61 evaluating picoplatin 61 NPM1 gene 61 HBeAg negative 61 refractory gastrointestinal stromal 61 immunotoxins 61 Hodgkin lymphoma HL 61 breast endometrial 61 Fludara ® 61 cells PBMC 61 NSCLC tumors 61 triggers apoptosis programmed 61 thymidylate synthase 61 Squamous 61 Peginterferon alfa 2b 61 bevacizumab Avastin R 61 malignant prostate 61 NF kB pathway 61 Tr DNA 61 Amgen Neulasta ® 61 redox active 61 MAGE A3 61 maternally inherited 61 extramedullary 61 Epothilones 61 FUS1 61 eIF 4E 61 novel therapeutic antibodies 61 sarcoma melanoma 61 anti angiogenic agents 61 HepG2 cells 61 renal fibrosis 61 Panzem R NCD 61 pediatric acute lymphoblastic 61 prostate adenocarcinoma 61 5 FU leucovorin 61 TRAIL R2 61 EGFR mutations 61 III EGFRvIII 61 refractory acute myeloid 61 gemcitabine Gemzar ® 61 gamma globin gene 61 hormone refractory 61 metastatic malignant 61 ADAMTS# 61 pan HDAC inhibitor 61 Zalypsis 61 CEA CD# Her2 61 auristatin 61 novel immunotherapies 61 histologic subtype 61 fibrotic disease 61 anionic backbone 61 colony stimulating factors 61 neoadjuvant setting 61 cisplatin chemotherapy 61 B Raf 61 RAS RAF MEK 61 Campath alemtuzumab 61 Metastatic colorectal cancer 61 upregulating 61 Hsp# inhibition 61 cytokine refractory 61 protein synthesis machinery 61 lenalidomide dexamethasone 61 molecular biomarkers 61 polycythemia vera PV 61 coagulation disorders 61 MyVax ® 61 cetuximab Erbitux R 61 radiolabeled TM# 61 vascular disrupting agents 61 Vidofludimus 61 recurrent ovarian 61 immunomodulatory properties 61 IgG1 monoclonal antibody 61 antisense therapies 61 cirrhosis liver failure 61 Multiple Myeloma MM 61 Waldenstrom macroglobulinemia 61 JAK inhibitors 61 Trastuzumab DM1 61 leukocyte adhesion 61 mitogen activated protein kinases 61 prognostic biomarker 61 thyroid carcinoma 61 activin receptor type 61 neuropilin 61 atypical hemolytic uremic syndrome 61 immunoregulatory 61 Upregulation 61 prostate cancer CaP 61 leukemia lymphomas 61 beta islets 61 hESC derived 61 pan histone deacetylase 61 gene rearrangements 61 evaluating tivozanib 61 EGFR TK 61 Src kinase 61 radiation chemoradiation 61 tumor metastases 61 protein tyrosine phosphatase 1B 61 MVA BN ® 61 Rituxan rituximab 61 cellular prion protein 61 Raf MEK ERK 61 interleukin IL -# 61 proteasome inhibitor 61 stem cell pluripotency 61 EGF receptor 61 sorafenib Nexavar 61 systemic ALCL 61 unresectable locally advanced 61 FGFR 61 ALK inhibitors 61 immune modulator 61 pancreatic islet 61 polysaccharide polymer 61 albumin bound paclitaxel 61 ERBB4 61 HIF 1α 61 V#E 61 NS3 protease 61 VEGFR2 inhibitor 61 metastatic malignant melanoma 61 MEK inhibitors 61 ErbB2 positive 61 Preclinical studies suggest 61 DNA intercalator 61 Prolastin A1PI 61 Omacetaxine 61 fibrocytes 61 gemcitabine cisplatin 61 serine threonine kinase 61 MyVax R 61 ErbB3 61 TTF Therapy 61 Lymphocytes 61 multivessel coronary artery 61 haematologic 61 galiximab 61 Clusterin 61 VEGF inhibitors 61 chromosome #p# [002] 61 Cloretazine R 61 myeloproliferative disorders 61 adhesion molecule EpCAM expressing 61 Myelodysplastic syndromes 61 liver metastasis 61 HER1 61 recombinant erythropoietin 61 hpSC 61 IMiDs R 61 trabectedin 61 acute myeloid 61 papillomaviruses 61 Circulating tumor cells 61 NS5B 61 HyperAcute 61 cytotoxic T lymphocyte 61 Basal cell 61 Cryptococcus neoformans 61 hematopoietic cancers 61 Affibody ® molecules 61 LRAT 61 AAG geldanamycin analog 61 trastuzumab Herceptin ® 61 CDH1 61 sorafenib Nexavar ® 61 NS4A 61 FGFR2 61 acetonide FA 61 MDR1 61 erlotinib Tarceva 61 Treg cell 61 Polymorphisms 61 thalassemia sickle cell 61 ADVEXIN therapy 61 acid phosphatase PAP 61 severe malignant osteopetrosis 61 anaplastic lymphoma kinase 61 cervical prostate 60 Leydig cells 60 KRAS mutation 60 Genetic variations 60 mycosis fungoides 60 paclitaxel cisplatin 60 anti EGFR antibody 60 selective inhibition 60 stage IIIB IV 60 unmutated 60 myelodysplastic myeloproliferative diseases 60 stage IIIb IV 60 CD# CEA 60 haematopoietic stem cell 60 keratinocyte 60 HuLuc# 60 mediated inhibition 60 Cx# [002] 60 myeloid 60 tumor xenograft models 60 lung carcinomas 60 upregulates 60 substantially excreted 60 treating sarcoma testicular 60 standard chemotherapy regimens 60 Glioblastoma multiforme GBM 60 mRCC 60 ANGPTL4 60 antisense oligonucleotides 60 sapacitabine CYC# 60 pancreatic colon 60 TÎ ² 4 60 DNA methyltransferases 60 vimentin 60 IDH2 60 cytomegalovirus CMV 60 antimetabolites 60 hematologic disorders 60 taxane refractory 60 Smac mimetics 60 cytotoxin 60 irreversible inhibitor 60 HMGCR 60 p# mutations 60 adult mesenchymal stem 60 MKC# MT 60 oral squamous cell 60 pancreatic ductal 60 PKCi 60 hematopoietic malignancies 60 chronic granulomatous disease 60 CMV vaccine 60 CCR1 60 vaccine GRNVAC1 60 cancer mCRC 60 Taxol ® 60 telomerase inhibitor 60 taxane chemotherapy 60 metastatic renal cell 60 NPM1 mutation 60 lymphocytic 60 Akt activation 60 cyclophosphamide methotrexate 60 HLA DR4 immune 60 capsular polysaccharide 60 biologic pathway 60 tumoral 60 oncoproteins 60 pancreatic carcinoma 60 telomerase reverse transcriptase 60 cellular immunotherapy 60 Insegia 60 epithelial cancers 60 leukemia lymphoma multiple myeloma 60 oral clodronate 60 pharmacogenomic translational research 60 xenograft model 60 murine models 60 p# mitogen activated 60 Chinese hamster ovary 60 anaplastic lymphoma kinase ALK 60 isotype 60 proliferation apoptosis 60 neurite outgrowth 60 HCV protease inhibitors 60 prognostic indicator 60 Pralatrexate 60 human IgG1 monoclonal 60 p# MAPK 60 cell adhesion molecule 60 androgen dependent 60 conventional chemotherapies 60 gene polymorphism 60 liposomal formulation 60 Nexavar tablets 60 metaplasia 60 hematological cancers 60 fallopian tube carcinoma 60 tests miRview TM 60 histone deacetylation 60 causal variants 60 sequence homology 60 Orally administered 60 locoregional recurrence 60 nutlin 3a 60 corticosteroid dexamethasone 60 endogenous ligands 60 Potelligent Technology 60 EGFR tyrosine kinase inhibitor 60 hormonally responsive 60 ANCA associated 60 vidofludimus 60 MTHFR 60 follicular Non Hodgkin 60 herpesviruses 60 vitro pharmacology 60 c myc gene 60 Addex Pharmaceuticals www.addexpharma.com discoverMunsif Khan spokesman 60 transfection reagents 60 CYP#A# CYP#D# 60 JAK2 60 pharmacodynamic markers 60 Xelox 60 cyclin dependent kinase 60 protein tyrosine kinase 60 urothelial cancer 60 oncoprotein 60 Imatinib mesylate 60 TLR3 60 myeloid metaplasia 60 proximal tubular 60 refractory chronic myeloid 60 cytopathic 60 oncogenic transformation 60 CD#c 60 recurrent epithelial ovarian 60 vitro assay 60 squamous 60 pro angiogenic 60 Lenocta 60 chromosomal mutations 60 R Saizen R 60 colorectal adenocarcinoma 60 ChronVac C R 60 brivanib 60 CTAP# 60 relapsing remitting MS RRMS 60 docetaxel Taxotere ® 60 Cytotoxic T 60 chronic eosinophilic leukemia 60 LNCaP cells 60 combining voreloxin 60 GISTs 60 IgG1 60 thiazolides 60 GPC5 60 BRAF kinase 60 myeloma cells 60 protein tyrosine phosphatases 60 JVRS 60 CDK4 60 hematopoietic cell 60 Personalized Immunotherapy 60 carbohydrate antigens 60 investigational monoclonal antibody 60 coexpression 60 Aviptadil 60 glucokinase activators 60 Human cl 60 nonhereditary 60 GW# [003] 60 JAK3 60 HER2 HER2 60 vincristine doxorubicin 60 GNAQ 60 liver cancers hypercholesterolemia 60 anastrazole 60 RKIP 60 nephronophthisis 60 cyclin dependent kinases CDKs 60 E#F# 60 NOD SCID mice 60 BCG refractory 60 breast cancer subtypes 60 Surgical resection 60 ovarian endometrial 60 ErbB3 HER3 60 BCL2 60 anthracycline containing 60 alvespimycin 60 EGFr expressing metastatic colorectal 60 A1PI 60 TGF b 60 granulosa cell 60 induced anemia 60 telomerase therapeutic 60 synovial cells 60 Chlamydia psittaci 60 Bleomycin 60 IMiDs ® compound 60 Septin9 biomarker 60 cisplatin gemcitabine 60 AEG# 60 NPC 1C 60 histone deacetylase HDAC 60 Voreloxin 60 complement inhibitor eculizumab 60 CEACAM1 60 Solazed TM 60 malignant pleural mesothelioma 60 leukaemias 60 ® bortezomib 60 humanized therapeutic 60 investigational immunotherapy 60 NNRTI resistant virus 60 ZFN modified 60 aMCI precursor 60 non squamous 60 immunomodulatory therapy 60 lymphoma multiple myeloma 60 node metastases 60 immunotoxin 60 neurotrophic 60 Fc receptor 60 systemically administered 60 WT1 60 Her2 positive 60 somatostatin receptor 60 transthyretin amyloidosis 60 HIF 1alpha 60 topoisomerase II inhibitors 60 essential thrombocythemia 60 busulfan 60 cells multiply uncontrollably 60 iobenguane 60 PI3K AKT 60 transthyretin TTR 60 hormone receptor negative 60 Stromal 60 hTERT 60 cytoreduction 60 heparanase 60 thymidine kinase 60 Bezielle 60 carbohydrate polymer 60 TRAF1 C5 60 lung ovary 60 glioma cells 60 Protein Kinase C 60 immuno therapeutic 60 urothelial carcinoma 60 KRAS mutation status 60 gemcitabine Gemzar 60 oncogenic mutations 60 Symadex 60 ATTR CM 60 B7 H4 60 transiently transfected 60 non nucleoside 60 deCODE AF TM 60 xenograft 60 OnDose TM 60 lenalidomide Revlimid R 60 surgically resectable 60 diabetic kidney 60 p#INK#a 60 TRAIL receptor antibodies 60 metastatic carcinoma 60 human leukocyte antigens 60 Provecta TM 60 immunotherapeutic agent 60 dysplastic lesions caused 60 serous ovarian cancer 60 immune dysregulation 60 ZNF# 60 deacetylase 60 HNSCC 60 murine model 60 Aflibercept 60 advanced pancreatic neuroendocrine 60 neuroblastoma tumors 60 monoclonal antibody conjugated 60 bexarotene 60 IMiDs ® 60 metastatic renal cell carcinoma 60 C5aR 60 prostaglandin synthesis 60 intratumoral injection 60 diagnostic molecular imaging 60 protein kinase inhibitor 60 kallikrein 60 CDKN2A 60 CCR9 60 commercializes oncology 60 chronic HBV 60 gastrointestinal stromal tumor GIST 60 insulin secreting beta 60 ATC ovarian cancer 60 transduce 60 lipoglycopeptide 60 Ii protein 60 lung fibrosis 60 Hedgehog inhibitor 60 Genetic variants 60 pretransplant 60 drug conjugates ADCs 60 BCR ABL protein 60 Her2/neu 60 HGS ETR1 60 neoplastic cells 60 nonmelanoma